PeptideSearch

VIP

Tested in people

Get notified when the evidence changes.

It has been tested in people, but it is not an approved medicine. The studies are usually small.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-05-14

Also called Vasoactive Intestinal Peptide / Aviptadil / Zyesami

A natural body signal involved in inflammation and blood flow. Tested in people for lung conditions.

Official status: 503A Category 1 – nominated, still under FDA evaluation · Checked 2026-05-14

Can a doctor prescribe this?

Small pharmacy (503A)
Category 1 — under review, allowed for now
Large outsourcing facility (503B)
Never put forward to FDA

Not approved in the US. It has been studied under investigational status for lung conditions. The FDA has "Vasoactive Intestinal Peptide" in Category 1 of the substances it is still working through for small-pharmacy (503A) compounding, so while that review runs the FDA says it does not plan to act against a pharmacy that makes it. That is not the same as being on the final list.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

Lab suppliers we list: 3

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

This is a sample, not the whole literature.

About 122,000 papers mentioning this compound have been published. We show a selected sample of 98 of them, not the full literature. How we choose them · count checked 2026-08-23

Spot an error? corrections@peptidesearch.org

What has happened so far

  1. 14 May 2026503A

    FDA lists "Vasoactive Intestinal Peptide" under 503A Category 1: Bulk Drug Substances Under Evaluation. Category 1 means FDA does not intend to act against a pharmacy compounding it while the evaluation continues; it is not the final 503A Bulks List. Read from the FDA 503A category document headed "Updated May 14, 2026".

    FDA

We'll email you when a new study, trial or status change lands for VIP. Unsubscribe in one click.